Following Isis Pharmaceuticals' strong presentation at the JPMorgan Healthcare Conference, the market sent shares up 8%. Although a lot of attention is on HoFH drug Kynamro, Isis doesn't have all its eggs in one basket, as nine pipeline drugs will reach important benchmarks this year. In this video, Motley Fool health care analyst David Williamson tells investors what the company's 2013 prospects look like.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock picking service: SupernovaJust click here now for instant access.


The article Isis Wins at Wooing Wall Street originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid. Max Macaluso has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Portfolio Basics

What are stocks? Learn how to start investing.

View Course »

What Is Your Risk Tolerance?

Answer the question "What type of investor am I?".

View Course »

Add a Comment

*0 / 3000 Character Maximum